NCT03800953Unknown2 期
Chemotherapy/Avelumab Plus Radiotherapy to Primary Esophageal Tumor for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma: The Ave-CRT Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- overall radiographic response
研究概览
简要总结
This is a single institutional, single arm, open labeled phase II study to assess the overall radiographic response of adding Avelumab to chemotherapy and palliative radiotherapy in patients with metastatic advanced esophageal squamous cell carcinoma.
详细描述
Avelumab belongs to the group of immune checkpoint blockade cancer therapies. Avelumab binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). In the case of avelumab, the formation of PD-1/PDL1 ligand pairs is blocked and CD8+ T cell immune response should be increased. This study comprises 2 phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. In the immune-chemoradiotherapy phase, patients are treated with PF-CRT and concomitant Avelumab. In the immune-chemotherapy phase, patients are treated with PF plus Avelumab. Overall radiological response, time to progression, overall survival and adverse events will be evaluated. Subjects' health-related quality of life will be assessed as well.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible for inclusion, patients must fulfill the following criteria:
- •Histologically proved squamous cell carcinoma of esophagus
- •Metastatic disease, which are defined by TNM system of American Joint Committee on Cancer (AJCC) Cancer Staging System (8th edition) in 2017, involving distant lymph node (para-aortic or cervical) metastasis and/or visceral metastasis (lung, liver) documented by radiological examinations
- •Age ≥ 20 years
- •ECOG Performance Status 0 or 1
- •Adequate bone marrow reserves within 2 weeks prior to registration, defined as:a. absolute neutrophil count (ANC) ≥ 1.5×109/L (1,500/μl)b. platelets ≥ 100×109/L (100,000/µl)c. hemoglobin ≥ 9.0 g/dl (may have been transfused)
- •Adequate liver function reserves within 2 weeks prior to registration, defined as:
- •hepatic transaminases (AST and ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN for subjects with documented metastatic disease to liver
- •serum total bilirubin ≤ 2.5 × upper limit of normal (ULN)
- •Adequate renal function within 2 weeks prior to registration: Creatinine ≤1.5 mg/dL
- •Negative serum or urine pregnancy test for women of childbearing potential
- •Women of childbearing potential and male participants must practice highly effective contraception throughout the study and for at least 30 days after last avelumab treatment administration if the risk of conception exists
- •Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent
排除标准
- •Patients fulfill any of the following criteria will be excluded from this trial
- •Prior radiotherapy to head and neck, chest, or abdomen
- •Tumor invasion to adjacent structures (T4 lesion)
- •Adenocarcinoma of esophagus or gastroesophageal junction.
- •No measurable metastatic target lesion(s) by RECIST criteria
- •Synchronously or metachronously diagnosed squamous cell carcinoma of aerodigestive way, other than esophageal cancer
- •Prior invasive malignancy
- •Prior organ transplantation including allogenic stem-cell transplantation
- •Current use of immunosuppressive medication, EXCEPT for the following:
- •intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)
- •systemic corticosteroids at physiologic doses '≤ 10 mg/day of prednisone or equivalent
- •steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- •Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:
- •Uncontrolled active infection requiring intravenous antibiotics at the time of registration
- •Transmural myocardial infarction < 6 months prior to registration
- •Unstable angina or congestive heart failure requiring hospitalization < 6 months prior to registration
- •Life-threatening uncontrolled clinically significant cardiac arrhythmias
- •Cerebral vascular accident/stroke (< 6 months prior to enrollment)
- •Congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- •Chronic obstructive pulmonary disease exacerbation or other respiratory illness including pulmonary fibrosis requiring hospitalization or precluding study therapy at the time of registration
- •Uncontrolled psychiatric disorder including recent (within the past year) or active suicidal ideation or behavior
- •Laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results
- •Immune colitis, inflammatory bowel disease, immune pneumonitis
- •Known history of testing positive for HIV or known acquired immunodeficiency syndrome."
- •Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
- •Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
- •Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3)"
- •Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic
研究组 & 干预措施
Avelumab (Bavencio)
Experimental
This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
干预措施: Avelumab (Drug)
结局指标
主要结局
overall radiographic response
时间窗: 6 months
overall radiographic response at six-month will be determined by iRECIST
次要结局
- New metastasis-free survival(up to 2 years)
- Best radiographic response(up to 2 years)
- Frequency of adverse events(up to 2 years)
- Heath-related quality of life(up to 2 years)
- Progression-free survival(up to 2 years)
- Overall survival(up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)Locally Advanced Esophageal and Gastric Cancers (EGC)NCT03064490Duke University35
终止
2 期
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell CarcinomaCarcinoma, Basal CellNCT02956889Istituto Clinico Humanitas14
Unknown
不适用
Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical CancerCervical Cancer Stage IVBNCT03175848Zhejiang Cancer Hospital48
进行中（未招募）
2 期
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)Esophageal Squamous Cell CarcinomasConcurrent ChemoradiotherapyImmunotherapyChemotherapyNCT05621707Shanghai Chest Hospital50
终止
2 期
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung CancerNon Small Cell Lung CancerStage III Non-small-cell Lung CancerNCT03871153Greg Durm, MD7